RT Journal Article
T1 Efficacy of rituximab in slowing down progression of rheumatoid arthritis–related interstitial lung disease: data from the NEREA Registry
A1 Vadillo, Cristina
A1 Nieto Barbero, María Asunción
A1 Romero-Bueno, Fredeswinda
A1 Leon, Leticia
A1 Sanchez-Pernaute, Olga
A1 Rodriguez-Nieto, Maria Jesus
A1 Freites, Dalifer
A1 Jover Jover, Juan Ángel
A1 Álvarez-Sala Walther, José Luis
A1 Abasolo, Lydia
AB ObjectivesTo asses the clinical course in RA-related interstitial lung disease (RA-ILD) patients with and without rituximab (RTX). The influence of other variables was also evaluated.MethodsA longitudinal multicentre study was conducted in RA diagnosed with ILD from 2007 until 2018 in Madrid. Patients were included in a registry [pNEumology RhEumatology Autoinmune diseases (NEREA)] from the time of ILD diagnosis. The main endpoint was functional respiratory impairment (FI), when there was a decline ≥5% in the predicted forced vital capacity compared with the previous one. Pulmonary function was measured at baseline and in follow-up visits every 6–12 months. The independent variable was therapy with RTX. Covariables included sociodemographic, clinical, radiological and other therapies. Survival techniques were used to estimate the incidence rate (IR) and 95% CI of functional impairment, expressed per 100 patient-semesters. Cox multivariate regression models were run to examine the influence of RTX and other covariates on FI. Results were expressed as the hazard ratio (HR) and CI.ResultsA total of 68 patients were included. FI occurred in 42 patients [IR 23.5 (95% CI 19, 29.1)] and 50% of them had FI within 1.75 years of an ILD diagnosis. A multivariate analysis showed that RTX exposure resulted in a lower risk of FI compared with non-exposure [HR 0.51 (95% CI 0.31, 0.85)]. Interstitial pneumonia, glucocorticoids, disease activity and duration also influenced FI.ConclusionRA-ILD patients deteriorate over time, with the median time free of impairment being <2 years. Patients exposed to RTX had a higher probability of remaining free of FI compared with other therapies. Other factors have also been identified.
PB Oxford university press
SN 1462-0324
YR 2020
FD 2020
LK https://hdl.handle.net/20.500.14352/134795
UL https://hdl.handle.net/20.500.14352/134795
LA eng
NO Vadillo, C., Nieto, M. A., Romero-Bueno, F., Leon, L., Sanchez-Pernaute, O., Rodriguez-Nieto, M. J., Freites, D., Jover, J. A., Álvarez-Sala, J. L., & Abasolo, L. (2020). Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford, England), 59(8), 2099–2108. https://doi.org/10.1093/rheumatology/kez673
NO Instituto de Salud Carlos III, Ministry of Health, Spain (Miguel Servet research contract: CP11/00189 to L.A.
NO Fondo de Investigaciones Sanitarias: PI18/01188
NO Red de Investigacio´ n en Inflamacio´ n y Enfermedades Reuma´ ticas: RD16/0012/0014)
DS Docta Complutense
RD 29 abr 2026